Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion Says New Data Prove Remsima SC Is A ‘Biobetter’

Subcutaneous Infliximab Shows Improved Outcomes Compared To Intravenous Version

Executive Summary

Celltrion says new data show that its Remsima SC subcutaneous infliximab biosimilar produces “statistically greater improvements in clinical outcomes” for rheumatoid arthritis patients compared to intravenous infliximab.

You may also be interested in...



Celltrion Calls For Harmonized Approach To ‘Biobetters’

A standardized, globally-accepted approach to ‘biobetters’ – biosimilars that offer improvements over the original reference drug – is needed to reduce trial duplication and allow products to come to market more quickly, Celltrion tells Generics Bulletin, at the same time as the company published data showing the benefits of its Remsima SC unique subcutaneous formulation of infliximab.

Celltrion’s Remsima SC Biosimilar Starts Strong In EU5 Countries

Celltrion is capitalizing on the earlier strength of its intravenous Remsima formulation to make waves with its innovative subcutaneous version, according to the results of a new study sampling nearly 250 gastroenterologists in EU5 countries.

Celltrion Healthcare Gears Up For Infliximab SC Launch

As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel